|
1
|
A causal role for ERG in neoplastic transformation of prostate epithelium.
|
Proc Natl Acad Sci U S A
|
2008
|
3.83
|
|
2
|
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.
|
Proc Natl Acad Sci U S A
|
2011
|
3.54
|
|
3
|
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.
|
Nat Med
|
2012
|
3.21
|
|
4
|
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.
|
J Clin Invest
|
2010
|
3.09
|
|
5
|
The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms.
|
Cancer Res
|
2006
|
3.07
|
|
6
|
A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
|
Proc Natl Acad Sci U S A
|
2006
|
2.89
|
|
7
|
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.
|
Cancer Cell
|
2011
|
2.86
|
|
8
|
Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
|
J Cell Biochem
|
2006
|
1.59
|
|
9
|
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.
|
Clin Cancer Res
|
2006
|
1.47
|
|
10
|
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.
|
PLoS One
|
2013
|
1.29
|
|
11
|
Conserved gene expression programs integrate mammalian prostate development and tumorigenesis.
|
Cancer Res
|
2009
|
1.20
|
|
12
|
Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect.
|
Clin Cancer Res
|
2010
|
1.09
|
|
13
|
Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma.
|
Clin Cancer Res
|
2005
|
1.06
|
|
14
|
Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
|
Cancer Lett
|
2006
|
1.06
|
|
15
|
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer.
|
Clin Cancer Res
|
2007
|
1.01
|
|
16
|
AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.
|
Neoplasia
|
2013
|
1.00
|
|
17
|
Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma.
|
Int J Cancer
|
2005
|
0.94
|
|
18
|
PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.
|
Mol Cancer Res
|
2013
|
0.92
|
|
19
|
Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.
|
Prostate
|
2013
|
0.89
|
|
20
|
Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer.
|
Proteomics Clin Appl
|
2011
|
0.89
|
|
21
|
Single cell transcriptomic analysis of prostate cancer cells.
|
BMC Mol Biol
|
2013
|
0.89
|
|
22
|
HE3235 inhibits growth of castration-resistant prostate cancer.
|
Neoplasia
|
2009
|
0.87
|
|
23
|
A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.
|
PLoS One
|
2013
|
0.86
|
|
24
|
Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition.
|
Clin Cancer Res
|
2009
|
0.83
|